Blog - etira

Breakthroughs that
make news.

See news releases about Etira, our stellar team,
our breakthrough innovations and our relentless steps to improve the survival of patients with advanced cancers.

Preclinical data on TNBC presented at SABCS 2022

Dallas, Texas. December 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast Cancer Symposium (SABCS). The SABCS is one of the world's…

Etira founder Dr. Jung-Mo Ahn highlighted in local press

News

Dallas, Texas. October 31, 2022. We are pleased to share two news articles from Dallas that describe how our brilliant chemist and founder, Dr. Jung-Mo Ahn discovered ERX-41. In his words, Dr. Ahn describes the discovery of ERX-41 as “It’s…

Oncology Times Highlights ERX-41

News

Dallas, Texas. October 10, 2022:etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar…

Etira selected as a 2022 BioNTX rising star

News

Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star. The BioNTX iC³ Life Science Summit is a two-day conference, held on September 22-23, 2022 that serves as a forum where…

ERX-41 Paper image selected for Nature Cancer cover

News

Dallas, Texas. July 7, 2022: On the cover of the July 2022 issue of Nature cancer is an image of the endoplasmic reticulum within a cell. Image courtesy of Dr. Andrew S. Moore, Janelia Research Campus. Cover Design by Allen Beattie. Highlighted…